Logo image of TRML

TOURMALINE BIO INC (TRML) Stock Fundamental Analysis

USA - NASDAQ:TRML - US89157D1054 - Common Stock

47.98 USD
0 (0%)
Last: 10/27/2025, 8:00:02 PM
47.98 USD
0 (0%)
After Hours: 10/27/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TRML. TRML was compared to 535 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TRML as it has an excellent financial health rating, but there are worries on the profitability. TRML is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRML has reported negative net income.
In the past year TRML has reported a negative cash flow from operations.
In the past 5 years TRML always reported negative net income.
TRML had a negative operating cash flow in each of the past 5 years.
TRML Yearly Net Income VS EBIT VS OCF VS FCFTRML Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of TRML (-32.79%) is better than 64.74% of its industry peers.
TRML has a better Return On Equity (-34.07%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA -32.79%
ROE -34.07%
ROIC N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
TRML Yearly ROA, ROE, ROICTRML Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRML so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRML Yearly Profit, Operating, Gross MarginsTRML Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

TRML has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TRML has been increased compared to 5 years ago.
TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TRML Yearly Shares OutstandingTRML Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
TRML Yearly Total Debt VS Total AssetsTRML Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 72.27 indicates that TRML is not in any danger for bankruptcy at the moment.
TRML has a Altman-Z score of 72.27. This is amongst the best in the industry. TRML outperforms 98.51% of its industry peers.
There is no outstanding debt for TRML. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 72.27
ROIC/WACCN/A
WACCN/A
TRML Yearly LT Debt VS Equity VS FCFTRML Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 24.68 indicates that TRML has no problem at all paying its short term obligations.
TRML's Current ratio of 24.68 is amongst the best of the industry. TRML outperforms 96.64% of its industry peers.
TRML has a Quick Ratio of 24.68. This indicates that TRML is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 24.68, TRML belongs to the top of the industry, outperforming 96.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.68
Quick Ratio 24.68
TRML Yearly Current Assets VS Current LiabilitesTRML Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

TRML shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.79%.
EPS 1Y (TTM)6.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TRML is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.61% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.34%
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%
EPS Next 5Y-7.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRML Yearly Revenue VS EstimatesTRML Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
TRML Yearly EPS VS EstimatesTRML Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRML. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRML. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRML Price Earnings VS Forward Price EarningsTRML Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRML Per share dataTRML EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as TRML's earnings are expected to decrease with -17.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRML!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TOURMALINE BIO INC

NASDAQ:TRML (10/27/2025, 8:00:02 PM)

After market: 47.98 0 (0%)

47.98

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners89.14%
Inst Owner Change-0.22%
Ins Owners10.48%
Ins Owner Change-2685.68%
Market Cap1.24B
Revenue(TTM)N/A
Net Income(TTM)-88.30M
Analysts70.67
Price Target48.96 (2.04%)
Short Float %3.72%
Short Ratio0.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)4.36%
Max EPS beat(2)6.49%
EPS beat(4)4
Avg EPS beat(4)5.03%
Min EPS beat(4)2.86%
Max EPS beat(4)6.49%
EPS beat(8)6
Avg EPS beat(8)-3.2%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.13%
PT rev (3m)-13.82%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)-6.12%
EPS NY rev (3m)-5.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.77
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)-3.43
EYN/A
EPS(NY)-4.17
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.35
OCFYN/A
SpS0
BVpS10.06
TBVpS10.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.79%
ROE -34.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.68
Quick Ratio 24.68
Altman-Z 72.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)137.69%
Cap/Depr(5y)218.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
EPS Next Y-33.34%
EPS Next 2Y-20.61%
EPS Next 3Y-17.39%
EPS Next 5Y-7.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-84.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.41%
OCF growth 3YN/A
OCF growth 5YN/A

TOURMALINE BIO INC / TRML FAQ

Can you provide the ChartMill fundamental rating for TOURMALINE BIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRML.


What is the valuation status of TOURMALINE BIO INC (TRML) stock?

ChartMill assigns a valuation rating of 0 / 10 to TOURMALINE BIO INC (TRML). This can be considered as Overvalued.


Can you provide the profitability details for TOURMALINE BIO INC?

TOURMALINE BIO INC (TRML) has a profitability rating of 1 / 10.


Can you provide the financial health for TRML stock?

The financial health rating of TOURMALINE BIO INC (TRML) is 8 / 10.


What is the expected EPS growth for TOURMALINE BIO INC (TRML) stock?

The Earnings per Share (EPS) of TOURMALINE BIO INC (TRML) is expected to decline by -33.34% in the next year.